Literature DB >> 24146190

The relationship between defibrillation threshold and total mortality.

Jason C Rubenstein1, Michael H Kim, Fred Morady, S Adam Strickberger.   

Abstract

BACKGROUND: The relationship between the defibrillation threshold (DFT) and total mortality is unclear.
METHODS: A university hospital prospectively maintained implantable defibrillator (ICD) database identified 508 patients who underwent ICD implantation and had DFT testing performed at implant. Patients were placed in one of three groups based on the implant DFT (high (≥20 J), moderate (19-11 J), or low DFT (≤10 J)).
RESULTS: Sixty-seven patients had a high DFT, 216 had a moderate DFT, and 225 had a low DFT. The mean left ventricular ejection fraction (LVEF) was 0.25, 0.28, and 0.30 in the high, moderate, and low DFT groups, respectively, (p = 0.04). There were significantly more patients with a subcutaneous electrode in the high DFT group (p < 0.001), more patients taking amiodarone (p < 0.001), and more patients on oral anticoagulation (p = 0.04). There were a total of 140 deaths during the follow-up period (mean 3.2 ± 1.7 years). There were 24 deaths in the high DFT group (35.8%), 62 in the moderate DFT group (28.7%), and 54 in the low DFT group (24.0%) (p = 0.05). Implant DFT was a significant predictor of mortality (p = 0.01), as was age, LVEF (p < 0.001), CAD (p = 0.01), amiodarone use (p = 0.02), and hematoma at implant (p = 0.01). An elevated DFT was an independent predictor of mortality after controlling for all significant univariate variables (p = 0.004).
CONCLUSIONS: A high-implant DFT predicts an adverse prognosis, even when an adequate ICD safety margin is present.

Entities:  

Mesh:

Year:  2013        PMID: 24146190     DOI: 10.1007/s10840-013-9831-5

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  15 in total

1.  Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.

Authors:  Stefan H Hohnloser; Paul Dorian; Robin Roberts; Michael Gent; Carsten W Israel; Eric Fain; Jean Champagne; Stuart J Connolly
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications.

Authors:  Himanshu H Shukla; Greg C Flaker; Vinod Jayam; David Roberts
Journal:  Pacing Clin Electrophysiol       Date:  2003-01       Impact factor: 1.976

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion?

Authors:  Andrea M Russo; William Sauer; Edward P Gerstenfeld; Henry H Hsia; David Lin; Joshua M Cooper; Sanjay Dixit; Ralph J Verdino; Hemal M Nayak; David J Callans; Vickas Patel; Francis E Marchlinski
Journal:  Heart Rhythm       Date:  2005-05       Impact factor: 6.343

6.  Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system.

Authors:  Denice M Hodgson; Mary R Olsovsky; Stephen R Shorofsky; Barry Daly; Michael R Gold
Journal:  Pacing Clin Electrophysiol       Date:  2002-04       Impact factor: 1.976

7.  Is defibrillation testing still necessary? A decision analysis and Markov model.

Authors:  Lorne J Gula; David Massel; Andrew D Krahn; Raymond Yee; Allan C Skanes; George J Klein
Journal:  J Cardiovasc Electrophysiol       Date:  2008-02-21

8.  Clinical characteristics and outcome of patients with high defibrillation thresholds. A multicenter study.

Authors:  A E Epstein; K A Ellenbogen; K A Kirk; G N Kay; S M Dailey; V J Plumb
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

9.  Clinical predictors of defibrillation energy requirements in patients treated with a nonthoracotomy defibrillator system. The ResQ Investigators.

Authors:  S A Strickberger; S L Brownstein; B L Wilkoff; A J Zinner
Journal:  Am Heart J       Date:  1996-02       Impact factor: 4.749

10.  Defibrillation testing of the implantable cardioverter defibrillator: when, how, and by whom?

Authors:  Luis A Pires
Journal:  Indian Pacing Electrophysiol J       Date:  2007-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.